PUTEAUX, France--(BUSINESS WIRE)--Regulatory News:
ORPEA S.A. (ISIN FR001400NLM4) (Paris:ORP) and Natixis ODDO BHF signed, on 26 March 2024, amendment no. 2 to the liquidity and market surveillance contract entered into on 30 November 2022, relating to its ordinary shares admitted to trading on Euronext Paris, in accordance with the Autorité des Marchés Financiers (AMF)’s decision no. 2021-01 dated 22 June 2021 related to the establishing of liquidity contracts on shares as accepted market practice.
Also within the limits of the AMF’s decision no. 2021-01 dated 22 June 2021, ORPEA S.A. decided to increase the resources allocated to the liquidity contract by €1,000,000.
The position after contribution of these new resources on 26 March 2024 is:
- 46 shares,
- 1,415,570.95 €.
About emeis
With 76,000 experts and professionals in healthcare, care, and supporting the most vulnerable among us, emeis operates in 20 countries with five core activities: psychiatric clinics, medical care and rehabilitation clinics, nursing homes, home care services, and assisted-living facilities.
Every year, emeis welcomes 267,000 residents, patients, and other beneficiaries. emeis is committed and taking action to rise to a major challenge facing our civilisation, i.e. the increase in the number of people put in a vulnerable position as a result of accidents, old age, or the rising number of cases of mental illness.
ORPEA S.A., the Group's parent company is 50.2 % owned by Caisse des Dépôts, CNP Assurances, MAIF, and MACSF Epargne Retraite. It is listed on the Euronext Paris stock exchange (ISIN: FR001400NLM4) and a member of the SBF 120 and CAC Mid 60 indices.
Website: www.emeis.com